Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

4O07

Identification of novel HSP90/isoform selective inhibitors using structure-based drug design. Demonstration of potential utility in treating CNS disorders such as Huntington's disease

4O07 の概要
エントリーDOI10.2210/pdb4o07/pdb
関連するPDBエントリー4O04 4O05 4O09 4O0B
分子名称Heat shock protein HSP 90-alpha, 2,7,7-trimethyl-9-[8-(2-methylpropyl)-1-oxo-1,2,3,4-tetrahydroisoquinolin-6-yl]-1,2,3,4,6,7,8,9-octahydro-5H-beta-carbolin-5-one (3 entities in total)
機能のキーワードchaperone, chaperone-chaperone inhibitor complex, chaperone/chaperone inhibitor
由来する生物種Homo sapiens (human)
細胞内の位置Cytoplasm : P07900
タンパク質・核酸の鎖数1
化学式量合計26616.99
構造登録者
Zuccola, H.J.,Ernst, J.T. (登録日: 2013-12-13, 公開日: 2014-04-09, 最終更新日: 2024-02-28)
主引用文献Ernst, J.T.,Neubert, T.,Liu, M.,Sperry, S.,Zuccola, H.,Turnbull, A.,Fleck, B.,Kargo, W.,Woody, L.,Chiang, P.,Tran, D.,Chen, W.,Snyder, P.,Alcacio, T.,Nezami, A.,Reynolds, J.,Alvi, K.,Goulet, L.,Stamos, D.
Identification of Novel HSP90 alpha / beta Isoform Selective Inhibitors Using Structure-Based Drug Design. Demonstration of Potential Utility in Treating CNS Disorders such as Huntington's Disease.
J.Med.Chem., 57:3382-3400, 2014
Cited by
PubMed Abstract: A structure-based drug design strategy was used to optimize a novel benzolactam series of HSP90α/β inhibitors to achieve >1000-fold selectivity versus the HSP90 endoplasmic reticulum and mitochondrial isoforms (GRP94 and TRAP1, respectively). Selective HSP90α/β inhibitors were found to be equipotent to pan-HSP90 inhibitors in promoting the clearance of mutant huntingtin protein (mHtt) in vitro, however with less cellular toxicity. Improved tolerability profiles may enable the use of HSP90α/β selective inhibitors in treating chronic neurodegenerative indications such as Huntington's disease (HD). A potent, selective, orally available HSP90α/β inhibitor was identified (compound 31) that crosses the blood-brain barrier. Compound 31 demonstrated proof of concept by successfully reducing brain Htt levels following oral dosing in rats.
PubMed: 24673104
DOI: 10.1021/jm500042s
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (1.86 Å)
構造検証レポート
Validation report summary of 4o07
検証レポート(詳細版)ダウンロードをダウンロード

248636

件を2026-02-04に公開中

PDB statisticsPDBj update infoContact PDBjnumon